RecruitingPhase 1Phase 2NCT06383572
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Sponsor
M.D. Anderson Cancer Center
Enrollment
44 participants
Start Date
Jun 26, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Cyclophosphamide, a drug called Decitabine, and others for people with lymphodepleting chemotherapy and myeloid malignancies. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCyclophosphamide
Given by IV
DRUGFludarabine phosphate
Given by IV
DRUGDecitabine
Given by IV
DRUGDexamethasone
Given by mouth
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06383572
Related Trials
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
NCT069306511 location
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT057965702 locations
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
NCT0739648018 locations
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
NCT066685841 location